On October 30, Huaxi Biotech announced that the company's strategic investment in Korea's botulinum toxin INIBO has been approved by the State Drug Administration, and the company is its sole partner in the mainland China market.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.